|
1
|
Tran DH, Kim D, Kesavan R, Brown H, Dey T,
Soflaee MH, Vu HS, Tasdogan A, Guo J, Bezwada D, et al: De novo and
salvage purine synthesis pathways across tissues and tumors. Cell.
187:3602–3618.e20. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zarrella S, Miranda MR, Covelli V, Restivo
I, Novi S, Pepe G, Tesoriere L, Rodriquez M, Bertamino A, Campiglia
P, et al: Endoplasmic reticulum stress and its role in metabolic
reprogramming of cancer. Metabolites. 15:2212025. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Villa E, Ali ES, Sahu U and Ben-Sahra I:
Cancer cells tune the signaling pathways to empower de novo
synthesis of nucleotides. Cancers (Basel). 11:6882019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murray AW: The biological significance of
purine salvage. Annu Rev Biochem. 40:811–826. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pareek V, Pedley AM and Benkovic SJ: Human
de novo purine biosynthesis. Crit Rev Biochem Mol Biol. 56:1–16.
2021. View Article : Google Scholar
|
|
6
|
Camici M, Garcia-Gil M, Pesi R, Allegrini
S and Tozzi MG: Purine-metabolising enzymes and apoptosis in
cancer. Cancers (Basel). 11:13542019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He J, Zou LN, Pareek V and Benkovic SJ:
Multienzyme interactions of the de novo purine biosynthetic protein
PAICS facilitate purinosome formation and metabolic channeling. J
Biol Chem. 298:1018532022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pedley AM and Benkovic SJ: A new view into
the regulation of purine metabolism: The purinosome. Trends Biochem
Sci. 42:141–154. 2017. View Article : Google Scholar
|
|
9
|
Lu M, Wu Y, Xia M and Zhang Y: The role of
metabolic reprogramming in liver cancer and its clinical
perspectives. Front Oncol. 14:14541612024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hon KW, Zainal Abidin SA, Othman I and
Naidu R: The crosstalk between signaling pathways and cancer
metabolism in colorectal cancer. Front Pharmacol. 12:7688612021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pandey S, Singh R, Habib N, Tripathi RM,
Kushwaha R and Mahdi AA: Regulation of hypoxia dependent
reprogramming of cancer metabolism: Role of HIF-1 and its potential
therapeutic implications in leukemia. Asian Pac J Cancer Prev.
25:1121–1134. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi JZ, Zhu YJ, Zhang MJ, Yan Y, Zhao LL,
Zhang HD, Liu Y, Wu WH, Cheng Z, Qiu CG, et al: Hypoxanthine
promotes pulmonary vascular remodeling and adenosine deaminase is a
therapeutic target for pulmonary hypertension. JACC Basic Transl
Sci. 10:1012732025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cuny GD, Suebsuwong C and Ray SS:
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: A patent
and scientific literature review (2002-2016). Expert Opin Ther Pat.
27:677–690. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cholewiński G, Iwaszkiewicz-Grześ D, Prejs
M, Głowacka A and Dzierzbicka K: Synthesis of the inosine
5'-monophosphate dehydrogenase (IMPDH) inhibitors. J Enzyme Inhib
Med Chem. 30:550–563. 2015. View Article : Google Scholar
|
|
15
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weinhouse S: The Warburg hypothesis fifty
years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol.
87:115–126. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Marín-Hernández A and Saavedra E: Energy metabolism in tumor cells.
FEBS J. 274:1393–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Saavedra E, Marín-Hernández A and Gallardo-Pérez JC: The
bioenergetics of cancer: Is glycolysis the main ATP supplier in all
tumor cells? Biofactors. 35:209–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B
and Liu P: NCAPD3 enhances Warburg effect through c-myc and E2F1
and promotes the occurrence and progression of colorectal cancer. J
Exp Clin Cancer Res. 41:1982022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fang J, Luo S and Lu Z: HK2: Gatekeeping
microglial activity by tuning glucose metabolism and mitochondrial
functions. Mol Cell. 83:829–831. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fantin VR, St-Pierre J and Leder P:
Attenuation of LDH-A expression uncovers a link between glycolysis,
mitochondrial physiology, and tumor maintenance. Cancer Cell.
9:425–434. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Christofk HR, Vander Heiden MG, Harris MH,
Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Christofk HR, Vander Heiden MG, Wu N,
Asara JM and Cantley LC: Pyruvate kinase M2 is a
phosphotyrosine-binding protein. Nature. 452:181–186. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Patra KC and Hay N: The pentose phosphate
pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Riganti C, Gazzano E, Polimeni M, Aldieri
E and Ghigo D: The pentose phosphate pathway: An antioxidant
defense and a crossroad in tumor cell fate. Free Radical Biol Med.
53:421–436. 2012. View Article : Google Scholar
|
|
27
|
TeSlaa T, Ralser M, Fan J and Rabinowitz
JD: The pentose phosphate pathway in health and disease. Nat Metab.
5:1275–1289. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Yang K, Xie Q, Wu Q, Mack SC, Shi
Y, Kim LJY, Prager BC, Flavahan WA, Liu X, et al: Purine synthesis
promotes maintenance of brain tumor initiating cells in glioma. Nat
Neurosci. 20:661–673. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Manganelli G, Masullo U, Passarelli S and
Filosa S: Glucose-6-phosphate dehydrogenase deficiency:
Disadvantages and possible benefits. Cardiovasc Hematol Disord Drug
Targets. 13:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan TWM, Bruntz RC, Yang Y, Song H,
Chernyavskaya Y, Deng P, Zhang Y, Shah PP, Beverly LJ, Qi Z, et al:
De novo synthesis of serine and glycine fuels purine nucleotide
biosynthesis in human lung cancer tissues. J Biol Chem.
294:13464–13477. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu D, Zhang K, Khan FA, Pandupuspitasari
NS, Guan K, Sun F and Huang C: A comprehensive review on signaling
attributes of serine and serine metabolism in health and disease.
Int J Biol Macromol. 260:1296072024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shunxi W, Xiaoxue Y, Guanbin S, Li Y,
Junyu J and Wanqian L: Serine metabolic reprogramming in
tumorigenesis, tumor immunity, and clinical treatment. Adv Nutr.
14:1050–1066. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Geeraerts SL, Heylen E, De Keersmaecker K
and Kampen KR: The ins and outs of serine and glycine metabolism in
cancer. Nat Metab. 3:131–141. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tibbetts AS and Appling DR:
Compartmentalization of Mammalian folate-mediated one-carbon
metabolism. Annu Rev Nutr. 30:57–81. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huo FC, Xie M, Zhu ZM, Zheng JN and Pei
DS: SHMT2 promotes the tumorigenesis of renal cell carcinoma by
regulating the m6A modification of PPAT. Genomics. 114:1104242022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hennequart M, Labuschagne CF, Tajan M,
Pilley SE, Cheung EC, Legrave NM, Driscoll PC and Vousden KH: The
impact of physiological metabolite levels on serine uptake,
synthesis and utilization in cancer cells. Nat Commun. 12:61762021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
DeNicola GM, Chen PH, Mullarky E, Sudderth
JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, et al: NRF2
regulates serine biosynthesis in non-small cell lung cancer. Nat
Genet. 47:1475–1481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Locasale JW, Grassian AR, Melman T,
Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen
T, Sharfi H, et al: Phosphoglycerate dehydrogenase diverts
glycolytic flux and contributes to oncogenesis. Nat Genet.
43:869–874. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Locasale JW: Serine, glycine and
one-carbon units: Cancer metabolism in full circle. Nat Rev Cancer.
13:572–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kamynina E, Lachenauer ER, DiRisio AC,
Liebenthal RP, Field MS and Stover PJ: Arsenic trioxide targets
MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis.
Proc Natl Acad Sci USA. 114:E2319–E2326. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu
Z, Boggon TJ, Jin P, Yi H, Wright ER, et al: Glutamate
dehydrogenase 1 signals through antioxidant glutathione peroxidase
1 to regulate redox homeostasis and tumor growth. Cancer Cell.
27:257–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yelamanchi SD, Jayaram S, Thomas JK,
Gundimeda S, Khan AA, Singhal A, Keshava Prasad TS, Pandey A,
Somani BL and Gowda H: A pathway map of glutamate metabolism. J
Cell Commun Signal. 10:69–75. 2016. View Article : Google Scholar :
|
|
43
|
Choi YK and Park KG: Targeting glutamine
metabolism for cancer treatment. Biomol Ther (Seoul). 26:19–28.
2018. View Article : Google Scholar :
|
|
44
|
Vanhove K, Derveaux E, Graulus GJ,
Mesotten L, Thomeer M, Noben JP, Guedens W and Adriaensens P:
Glutamine addiction and therapeutic strategies in lung cancer. Int
J Mol Sci. 20:2522019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang B, Chen Y, Bao L and Luo W: GPT2 is
induced by hypoxia-inducible factor (HIF)-2 and promotes
glioblastoma growth. Cells. 11:25972022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim M, Gwak J, Hwang S, Yang S and Jeong
SM: Mitochondrial GPT2 plays a pivotal role in metabolic adaptation
to the perturbation of mitochondrial glutamine metabolism.
Oncogene. 38:4729–4738. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shen Y, Huang Q, Zhang Y, Hsueh CY and
Zhou L: A novel signature derived from metabolism-related genes GPT
and SMS to predict prognosis of laryngeal squamous cell carcinoma.
Cancer Cell Int. 22:2262022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ahn CS and Metallo CM: Mitochondria as
biosynthetic factories for cancer proliferation. Cancer Metab.
3:12015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Krall AS, Xu S, Graeber TG, Braas D and
Christofk HR: Asparagine promotes cancer cell proliferation through
use as an amino acid exchange factor. Nat Commun. 7:114572016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cai DJ, Zhang ZY, Bu Y, Li L, Deng YZ, Sun
LQ, Hu CP and Li M: Asparagine synthetase regulates lung-cancer
metastasis by stabilizing the β-catenin complex and modulating
mitochondrial response. Cell Death Dis. 13:5662022. View Article : Google Scholar
|
|
51
|
Ma G, Zhang Z, Li P, Zhang Z, Zeng M,
Liang Z, Li D, Wang L, Chen Y, Liang Y and Niu H: Reprogramming of
glutamine metabolism and its impact on immune response in the tumor
microenvironment. Cell Commun Signal. 20:1142022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Metallo CM, Gameiro PA, Bell EL, Mattaini
KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L,
et al: Reductive glutamine metabolism by IDH1 mediates lipogenesis
under hypoxia. Nature. 481:380–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Spinelli JB and Haigis MC: The
multifaceted contributions of mitochondria to cellular metabolism.
Nat Cell Biol. 20:745–754. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bertero T, Oldham WM, Grasset EM, Bourget
I, Boulter E, Pisano S, Hofman P, Bellvert F, Meneguzzi G, Bulavin
DV, et al: Tumor-stroma mechanics coordinate amino acid
availability to sustain tumor growth and malignancy. Cell Metab.
29:124–140.e10. 2019. View Article : Google Scholar
|
|
55
|
Sullivan LB, Gui DY, Hosios AM, Bush LN,
Freinkman E and Vander Heiden MG: Supporting aspartate biosynthesis
is an essential function of respiration in proliferating cells.
Cell. 162:552–563. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Krall AS, Mullen PJ, Surjono F, Momcilovic
M, Schmid EW, Halbrook CJ, Thambundit A, Mittelman SD, Lyssiotis
CA, Shackelford DB, et al: Asparagine couples mitochondrial
respiration to ATF4 activity and tumor growth. Cell Metab.
33:1013–1026.e6. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Newman AC and Maddocks ODK: One-carbon
metabolism in cancer. Br J Cancer. 116:1499–1504. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li T, Song LL, Zhang YW, Han YL, Zhan ZY,
Xv Z, Li Y, Tang Y, Yang Y, Wang S, et al: Molecular mechanism of
c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's
lymphoma. J Cell Mol Med. 24:6704–6715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Macmillan AC, Karki B, Yang JC, Gertz KR,
Zumwalde S, Patel JG, Czyzyk-Krzeska MF, Meller J and Cunningham
JT: PRPS activity tunes redox homeostasis in Myc-driven lymphoma.
Redox Biol. 84:1036492025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu T, Wang Z, Ye L, Duan Y, Jiang H, He
H, Xiao L, Wu Q, Xia Y, Yang M, et al: Nucleus-exported CLOCK
acetylates PRPS to promote de novo nucleotide synthesis and liver
tumour growth. Nat Cell Biol. 25:273–284. 2023.PubMed/NCBI
|
|
61
|
Song L, Li P, Sun H, Ding L, Wang J, Li B,
Zhou BS, Feng H and Li Y: PRPS2 mutations drive acute lymphoblastic
leukemia relapse through influencing PRPS1/2 hexamer stability.
Blood Sci. 5:39–50. 2022. View Article : Google Scholar
|
|
62
|
Lv Y, Wang X, Li X, Xu G, Bai Y, Wu J,
Piao Y, Shi Y, Xiang R and Wang L: Nucleotide de novo synthesis
increases breast cancer stemness and metastasis via cGMP-PKG-MAPK
signaling pathway. PLoS Biol. 18:e30008722020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Goswami MT, Chen G, Chakravarthi BV, Pathi
SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG,
Palanisamy N, et al: Role and regulation of coordinately expressed
de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.
Oncotarget. 6:23445–23461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Liu B, Song M, Qin H, Zhang B, Liu Y, Sun
Y, Ma Y and Shi T: Phosphoribosyl Pyrophosphate amidotransferase
promotes the progression of thyroid cancer via regulating pyruvate
kinase M2. Onco Targets Ther. 13:7629–7639. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kitagawa Y, Kondo S, Fukuyo M, Wakae K,
Dochi H, Mizokami H, Komura S, Kobayashi E, Hirai N, Ueno T, et al:
Phosphoribosyl pyrophosphate amidotransferase: Novel biomarker and
therapeutic target for nasopharyngeal carcinoma. Cancer Sci.
115:3587–3595. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Ding M, Ma C, Lin Y, Fang H, Xu Y, Wang S,
Chen Y, Zhou J, Gao H, Shan Y, et al: Therapeutic targeting de novo
purine biosynthesis driven by β-catenin-dependent PPAT upregulation
in hepatoblastoma. Cell Death Dis. 16:1792025. View Article : Google Scholar
|
|
67
|
Huang F, Ni M, Chalishazar MD, Huffman KE,
Kim J, Cai L, Shi X, Cai F, Zacharias LG, Ireland AS, et al:
Inosine monophosphate dehydrogenase dependence in a subset of small
cell lung cancers. Cell Metab. 28:369–382.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zheng MM, Li JY, Guo HJ, Zhang J, Wang LS,
Jiang KF, Wu HH, He QJ, Ding L and Yang B: IMPDH inhibitors
upregulate PD-L1 in cancer cells without impairing immune
checkpoint inhibitor efficacy. Acta Pharmacol Sin. 46:1058–1067.
2025. View Article : Google Scholar
|
|
69
|
Zhao JZ, Wang W, Liu T, Zhang L, Lin DZ,
Yao JY, Peng X, Jin G, Ma TT, Gao JB, et al: MYBL2 regulates de
novo purine synthesis by transcriptionally activating IMPDH1 in
hepatocellular carcinoma cells. BMC Cancer. 22:12902022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kofuji S, Hirayama A, Eberhardt AO,
Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto
N, Kitahara S, et al: IMP dehydrogenase-2 drives aberrant nucleolar
activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol.
21:1003–1014. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liu X, Wang J, Wu LJ, Trinh B and Tsai
RYL: IMPDH inhibition decreases TERT expression and synergizes the
cytotoxic effect of chemotherapeutic agents in glioblastoma cells.
Int J Mol Sci. 25:59922024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liu X, Sato N, Yabushita T, Li J, Jia Y,
Tamura M, Asada S, Fujino T, Fukushima T, Yonezawa T, et al: IMPDH
inhibition activates TLR-VCAM1 pathway and suppresses the
development of MLL-fusion leukemia. EMBO Mol Med. 15:e156312023.
View Article : Google Scholar :
|
|
73
|
An S, Kumar R, Sheets ED and Benkovic SJ:
Reversible compartmentalization of de novo purine biosynthetic
complexes in living cells. Science. 320:103–106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Deng Y, Gam J, French JB, Zhao H, An S and
Benkovic SJ: Mapping protein-protein proximity in the purinosome. J
Biol Chem. 287:36201–36207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu D, Yang S, Yuan C, Zhang K, Tan J, Guan
K, Zeng H and Huang C: Targeting purine metabolism-related enzymes
for therapeutic intervention: A review from molecular mechanism to
therapeutic breakthrough. Int J Biol Macromol. 282:1368282024.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pedley AM, Pareek V and Benkovic SJ: The
purinosome: A case study for a mammalian metabolon. Annu Rev
Biochem. 91:89–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Chan CY, Zhao H, Pugh RJ, Pedley AM,
French J, Jones SA, Zhuang X, Jinnah H, Huang TJ and Benkovic SJ:
Purinosome formation as a function of the cell cycle. Proc Natl
Acad Sci USA. 112:1368–1373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Baresova V, Krijt M, Skopova V, Souckova
O, Kmoch S and Zikanova M: CRISPR-Cas9 induced mutations along de
novo purine synthesis in HeLa cells result in accumulation of
individual enzyme substrates and affect purinosome formation. Mol
Genet Metab. 119:270–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Pelet A, Skopova V, Steuerwald U, Baresova
V, Zarhrate M, Plaza JM, Hnizda A, Krijt M, Souckova O, Wibrand F,
et al: PAICS deficiency, a new defect of de novo purine synthesis
resulting in multiple congenital anomalies and fatal outcome. Hum
Mol Genet. 28:3805–3814. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chan CY, Pedley AM, Kim D, Xia C, Zhuang X
and Benkovic SJ: Microtubule-directed transport of purine
metabolons drives their cytosolic transit to mitochondria. Proc
Natl Acad Sci USA. 115:13009–13014. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
French JB, Jones SA, Deng H, Pedley AM,
Kim D, Chan CY, Hu H, Pugh RJ, Zhao H, Zhang Y, et al: Spatial
colocalization and functional link of purinosomes with
mitochondria. Science. 351:733–737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pedley AM, Boylan JP, Chan CY, Kennedy EL,
Kyoung M and Benkovic SJ: Purine biosynthetic enzymes assemble into
liquid-like condensates dependent on the activity of chaperone
protein HSP90. J Biol Chem. 298:1018452022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
French JB, Zhao H, An SO, Niessen S, Deng
YJ, Cravatt BF and Benkovic SJ: Hsp70/Hsp90 chaperone machinery is
involved in the assembly of the purinosome. Proc Natl Acad Sci USA.
110:2528–2533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Pedley AM, Karras GI, Zhang X, Lindquist S
and Benkovic SJ: Role of HSP90 in the regulation of de novo purine
biosynthesis. Biochemistry. 57:3217–3221. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yu J, Jin C, Su C, Moon D, Sun M, Zhang H,
Jiang X, Zhang F, Tserentsoodol N, Bowie ML, et al: Resilience and
vulnerabilities of tumor cells under purine shortage stress. Clin
Cancer Res. 31:4345–4360. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Stine ZE, Walton ZE, Altman BJ, Hsieh AL
and Dang CV: MYC, metabolism, and cancer. Cancer Discov.
5:1024–1039. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wunder T and Mueller-Cajar O: Biomolecular
condensates in photosynthesis and metabolism. Curr Opin Plant Biol.
58:1–7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Chou MC, Wang YH, Chen FY, Kung CY, Wu KP,
Kuo JC, Chan SJ, Cheng ML, Lin CY, Chou YC, et al: PAICS
ubiquitination recruits UBAP2 to trigger phase separation for
purinosome assembly. Mol Cell. 83:4123–4140.e12. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cunningham JT, Moreno MV, Lodi A, Ronen SM
and Ruggero D: Protein and nucleotide biosynthesis are coupled by a
single rate-limiting enzyme, PRPS2, to drive cancer. Cell.
157:1088–1103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Camicia R, Winkler HC and Hassa PO: Novel
drug targets for personalized precision medicine in
relapsed/refractory diffuse large B-cell lymphoma: A comprehensive
review. Mol Cancer. 14:2072015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Delos Santos K, Kwon E and Moon NS:
PRPS-associated disorders and the drosophila model of arts
syndrome. Int J Mol Sci. 21:48242020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhang L, Zhao X, Hu J, Li T, Chen HZ,
Zhang A, Wang H, Yu J and Zhang L: PRPS2 enhances RNA
m6A methylation by stimulating SAM synthesis through
enzyme-dependent and independent mechanisms. Nat Commun.
16:39662025. View Article : Google Scholar
|
|
93
|
Jing XQ, Wang XJ, Zhang T, Zhu WC, Fang Y,
Wu HX, Liu X, Ma D, Ji X, Jiang Y, et al: Cell-cycle-dependent
phosphorylation of PRPS1 fuels nucleotide synthesis and promotes
tumorigenesis. Cancer Res. 79:4650–4664. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhuo W, Xia H, Lan B, Chen Y, Wang X and
Liu J: Signature of immune-related metabolic genes predicts the
prognosis of hepatocellular carcinoma. Front Immunol.
15:14813312024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Liu C, Knudsen GM, Pedley AM, He J,
Johnson JL, Yaron TM, Cantley LC and Benkovic SJ: Mapping
post-translational modifications of de novo purine biosynthetic
enzymes: Implications for pathway regulation. J Proteome Res.
18:2078–2087. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kodama M, Oshikawa K, Shimizu H, Yoshioka
S, Takahashi M, Izumi Y, Bamba T, Tateishi C, Tomonaga T, Matsumoto
M and Nakayama KI: A shift in glutamine nitrogen metabolism
contributes to the malignant progression of cancer. Nat Commun.
11:13202020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Xiang H, Kasajima R, Azuma K, Tagami T,
Hagiwara A, Nakahara Y, Saito H, Igarashi Y, Wei F, Ban T, et al:
Multi-omics analysis-based clinical and functional significance of
a novel prognostic and immunotherapeutic gene signature derived
from amino acid metabolism pathways in lung adenocarcinoma. Front
Immunol. 15:13619922024. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Loftus SK, Baxter LL, Cronin JC, Fufa TD;
NISC Comparative Sequencing Program; Pavan WJ: Hypoxia-induced
HIF1α targets in melanocytes reveal a molecular profile associated
with poor melanoma prognosis. Pigment Cell Melanoma Res.
30:339–532. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wu Z, Nguyen PT, Sondhi V, Yao RW, Lu Z,
Dai T, Chiang JC, Cai F, Williams IM, Blatt EB, et al: NUDT5
regulates purine metabolism and thiopurine sensitivity by
interacting with PPAT. Science. 390:1134–1142. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hedstrom L: IMP dehydrogenase: Structure,
mechanism, and inhibition. Chem Rev. 109:2903–2928. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Calise SJ and Chan EKL: Anti-rods/rings
autoantibody and IMPDH filaments: An update after fifteen years of
discovery. Autoimmun Rev. 19:1026432020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kim HR, Roe JS, Lee JE, Hwang IY, Cho EJ
and Youn HD: A p53-inducible microRNA-34a downregulates Ras
signaling by targeting IMPDH. Biochem Biophys Res Commun.
418:682–688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Duan S, Huang W, Liu X, Liu X, Chen N, Xu
Q, Hu Y, Song W and Zhou J: IMPDH2 promotes colorectal cancer
progression through activation of the PI3K/AKT/mTOR and
PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Cancer Res.
37:3042018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Casado P, Rio-Machin A, Miettinen JJ,
Bewicke-Copley F, Rouault-Pierre K, Krizsan S, Parsons A, Rajeeve
V, Miraki-Moud F, Taussig DC, et al: Integrative phosphoproteomics
defines two biologically distinct groups of KMT2A rearranged acute
myeloid leukaemia with different drug response phenotypes. Signal
Transduct Target Ther. 8:802023. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liu W, Li J, Xu S, Wang Y, Li J, Wang S,
Fu L, Jiang M and Bai G: Phillyrin and its metabolites exert
antipyretic effects by targeting the NAD+ binding domain
of GAPDH, MDH2 and IDH2. Phytomedicine. 134:1559552024. View Article : Google Scholar
|
|
106
|
Kunjithapatham R and Ganapathy-Kanniappan
S: GAPDH with NAD+-binding site mutation competitively
inhibits the wild-type and affects glucose metabolism in cancer.
Biochim Biophys Acta Gen Subj. 1862:2555–2563. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bie M, Tang Y, Xia Y, Zhang Q, Tian Y,
Cheng C, Li X, Qi X and Kang F: HIF-1α mediates osteoclast-induced
disuse osteoporosis via cytoophidia in the femur of mice. Bone.
168:1166482023. View Article : Google Scholar
|
|
108
|
Ogawa-Iio A, Takeuchi K, Shigemi K,
Genoveso MJ, Niitsu H, Koh I, Ota Y, Yamane K, Hinoi T, Osaka N, et
al: IMPDH and GTP metabolism in cancer: Mechanisms, regulation, and
translational scope. Cancer Sci. 116:3250–3265. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ishitsuka K, Hideshima T, Hamasaki M, Raje
N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM,
et al: Novel inosine monophosphate dehydrogenase inhibitor VX-944
induces apoptosis in multiple myeloma cells primarily via
caspase-independent AIF/Endo G pathway. Oncogene. 24:5888–5896.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tzoneva G, Dieck CL, Oshima K,
Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H,
Yu J, Waanders E, Iacobucci I, et al: Clonal evolution mechanisms
in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature.
553:511–514. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Grusch M, Rosenberger G, Fuhrmann G, Braun
K, Titscher B, Szekeres T, Fritzer-Skekeres M, Oberhuber G, Krohn
K, Hengstschlaeger M, et al: Benzamide riboside induces apoptosis
independent of Cdc25A expression in human ovarian carcinoma N.1
cells. Cell Death Differ. 6:736–744. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Tian Y, Zhang J, Chen L and Zhang X: The
expression and prognostic role of IMPDH2 in ovarian cancer. Ann
Diagn Pathol. 46:1515112020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Sugimoto A, Watanabe T, Matsuoka K, Okuno
Y, Yanagi Y, Narita Y, Mabuchi S, Nobusue H, Sugihara E, Hirayama
M, et al: Growth transformation of B cells by epstein-barr virus
requires IMPDH2 induction and nucleolar hypertrophy. Microbiol
Spectr. 11:e00440232023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Szwed A, Kim E and Jacinto E: Regulation
and metabolic functions of mTORC1 and mTORC2. Physiol Rev.
101:1371–1426. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Demetriades C, Plescher M and Teleman AA:
Lysosomal recruitment of TSC2 is a universal response to cellular
stress. Nat Commun. 7:106622016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara
JM and Manning BD: mTORC1 induces purine synthesis through control
of the mitochondrial tetrahydrofolate cycle. Science. 351:728–733.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Fontana F, Giannitti G, Marchesi S and
Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous
liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Düvel K, Yecies JL, Menon S, Raman P,
Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S,
et al: Activation of a metabolic gene regulatory network downstream
of mTOR complex 1. Mol Cell. 39:171–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Saha A, Connelly S, Jiang J, Zhuang S,
Amador DT, Phan T, Pilz RB and Boss GR: Akt phosphorylation and
regulation of transketolase is a nodal point for amino acid control
of purine synthesis. Mol Cell. 55:264–276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Torrence ME, MacArthur MR, Hosios AM,
Valvezan AJ, Asara JM, Mitchell JR and Manning BD: The
mTORC1-mediated activation of ATF4 promotes protein and glutathione
synthesis downstream of growth signals. Elife. 10:e633262021.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Mollaoglu G, Guthrie MR, Böhm S,
Brägelmann J, Can I, Ballieu PM, Marx A, George J, Heinen C,
Chalishazar MD, et al: MYC drives progression of small cell lung
cancer to a variant neuroendocrine subtype with vulnerability to
aurora kinase inhibition. Cancer Cell. 31:270–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Liu YC, Li F, Handler J, Huang CR, Xiang
Y, Neretti N, Sedivy JM, Zeller KI and Dang CV: Global regulation
of nucleotide biosynthetic genes by c-Myc. PLoS One. 3:e27222008.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Huang F, Huffman KE, Wang Z, Wang X, Li K,
Cai F, Yang C, Cai L, Shih TS, Zacharias LG, et al: Guanosine
triphosphate links MYC-dependent metabolic and ribosome programs in
small-cell lung cancer. J Clin Invest. 131:e1399292021. View Article : Google Scholar :
|
|
125
|
Ali ES, Lipońska A, O'Hara BP, Amici DR,
Torno MD, Gao P, Asara JM, Yap MF, Mendillo ML and Ben-Sahra I: The
mTORC1-SLC4A7 axis stimulates bicarbonate import to enhance de novo
nucleotide synthesis. Mol Cell. 82:3284–3298.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Liu Y, Pareek V, Bhowmik D, Zhang X and
Benkovic SJ: Purinosomes and lysosomes interact to maintain the
purine pools. Int J Biochem Cell Biol. 186:1068302025. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Valvezan AJ, Turner M, Belaid A, Lam HC,
Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N,
Kwiatkowski DJ, et al: mTORC1 couples nucleotide synthesis to
nucleotide demand resulting in a targetable metabolic
vulnerability. Cancer Cell. 32:6242017. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Worby CA and Dixon JE: PTEN. Annu Rev
Biochem. 83:641–669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Zuo Z, Liu J, Sun Z, Cheng YW, Ewing M,
Bugge TH, Finkel T, Leppla SH and Liu S: ERK and c-Myc signaling in
host-derived tumor endothelial cells is essential for solid tumor
growth. Proc Natl Acad Sci USA. 120:e22119271202023. View Article : Google Scholar :
|
|
130
|
Liefwalker DF, Ryan M, Wang Z, Pathak KV,
Plaisier S, Shah V, Babra B, Dewson GS, Lai IK, Mosley AR, et al:
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and
MYC-driven lymphoid malignancies. Cancer Metab. 9:312021.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Mannava S, Grachtchouk V, Wheeler LJ, Im
M, Zhuang D, Slavina EG, Mathews CK, Shewach DS and Nikiforov MA:
Direct role of nucleotide metabolism in C-MYC-dependent
proliferation of melanoma cells. Cell Cycle. 7:2392–2400. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Trejo-Solís C, Castillo-Rodríguez RA,
Serrano-García N, Silva-Adaya D, Vargas-Cruz S, Chávez-Cortéz EG,
Gallardo-Pérez JC, Zavala-Vega S, Cruz-Salgado A and
Magaña-Maldonado R: Metabolic roles of HIF1, c-Myc, and p53 in
glioma cells. Metabolites. 14:2492024. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liu W, Ding Z, Tao Y, Liu S, Jiang M, Yi
F, Wang Z, Han Y, Zong H, Li D, et al: A positive feedback loop
between PFKP and c-Myc drives head and neck squamous cell carcinoma
progression. Mol Cancer. 23:1412024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ying H, Kimmelman AC, Lyssiotis CA, Hua S,
Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff
JL, et al: Oncogenic Kras maintains pancreatic tumors through
regulation of anabolic glucose metabolism. Cell. 149:656–670. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Santana-Codina N, Roeth AA, Zhang Y, Yang
A, Mashadova O, Asara JM, Wang X, Bronson RT, Lyssiotis CA, Ying H
and Kimmelman AC: Oncogenic KRAS supports pancreatic cancer through
regulation of nucleotide synthesis. Nat Commun. 9:49452018.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Jiang X, Wang T, Zhao B, Sun H, Dong Y, Ma
Y, Li Z, Wu Y, Wang K, Guan X, et al: KRASG12D-driven
pentose phosphate pathway remodeling imparts a targetable
vulnerability synergizing with MRTX1133 for durable remissions in
PDAC. Cell Rep Med. 6:1019662025. View Article : Google Scholar
|
|
137
|
Gao W, Xu Y, Chen T, Du Z, Liu X, Hu Z,
Wei D, Gao C, Zhang W and Li Q: Targeting oxidative pentose
phosphate pathway prevents recurrence in mutant Kras colorectal
carcinomas. PLoS Biol. 17:e30004252019. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Romero R, Sayin VI, Davidson SM, Bauer MR,
Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A,
Sánchez-Rivera FJ, et al: Keap1 loss promotes Kras-driven lung
cancer and results in dependence on glutaminolysis. Nat Med.
23:1362–1368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Krauß D, Moreno-Viedma V, Adachi-Fernandez
E, de Sá Fernandes C, Genger JW, Fari O, Blauensteiner B,
Kirchhofer D, Bradaric N, Gushchina V, et al: EGFR controls
transcriptional and metabolic rewiring in KRAS(G12D) colorectal
cancer. EMBO Mol Med. 17:1355–1392. 2025. View Article : Google Scholar
|
|
140
|
Meena JK, Wang JH, Neill NJ, Keough D,
Putluri N, Katsonis P, Koire AM, Lee H, Bowling EA, Tyagi S, et al:
MYC induces oncogenic stress through RNA decay and ribonucleotide
catabolism in breast cancer. Cancer Discov. 14:1699–1716. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ali ES, Sahu U, Villa E, O'Hara BP, Gao P,
Beaudet C, Wood AW, Asara JM and Ben-Sahra I: ERK2 phosphorylates
PFAS to mediate posttranslational control of de novo purine
synthesis. Mol Cell. 78:1178–1191.e6. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Cox AG, Hwang KL, Brown KK, Evason K,
Beltz S, Tsomides A, O'Connor K, Galli GG, Yimlamai D, Chhangawala
S, et al: Yap reprograms glutamine metabolism to increase
nucleotide biosynthesis and enable liver growth. Nat Cell Biol.
18:886–896. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Fujita M, Orisaka M, Mizutani T, Fujita Y,
Onuma T, Tsuyoshi H and Yoshida Y: YAP/TAZ Promote GLUT1 expression
and are associated with prognosis in endometrial cancer. Cancers
(Basel). 17:25542025. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Gao C and Wang Y: YAP: The nexus between
metabolism and cardiac remodeling. J Clin Invest. 132:e1576642022.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Yu H, Tang H, Deng C, Lin Q, Yu P, Chen S
and Ruan J: RRM2 improves cardiomyocyte proliferation after
myocardial ischemia reperfusion Injury through the Hippo-YAP
pathway. Dis Markers. 2021:50898722021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Shah SR, Ren C, Tippens ND, Park J,
Mohyeldin A, Wang S, Vela G, Martinez-Gutierrez JC, Margolis SS,
Schmidt S, et al: YAP controls cell migration and invasion through
a Rho GTPase switch. Sci Signal. 18:eadu37942025.PubMed/NCBI
|
|
147
|
Tu CE, Liu YF, Liu HW, Jiao CM, Liu Q,
Hung MC, Li P, Wan XB, Fan XJ and Wang YL: D-ribose-5-phosphate
inactivates YAP and functions as a metabolic checkpoint. J Hematol
Oncol. 18:22025. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Zhang H, Guo Z, Yi J, Wu J, Wang Y, Ren T,
Zhang Y, Zhao H, Wu N, Wei G and Zhang D: Thymic egress and
peripheral T cell homeostasis regulated by Rho GTPase-activating
protein 30. Cell Death Differ. 32:2294–2308. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Ahmad Mokhtar AM, Salikin NH, Haron AS,
Amin-Nordin S, Hashim IF, Mohd Zaini Makhtar M, Zulfigar SB and
Ismail NI: RhoG's role in T cell activation and function. Front
Immunol. 13:8450642022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Cantrell DA: GTPases and T cell
activation. Immunol Rev. 192:122–130. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Cronin SJF, Seehus C, Weidinger A, Talbot
S, Reissig S, Seifert M, Pierson Y, McNeill E, Longhi MS, Turnes
BL, et al: The metabolite BH4 controls T cell proliferation in
autoimmunity and cancer. Nature. 563:564–568. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Madsen HB, Peeters MJ, Straten PT and
Desler C: Nucleotide metabolism in the regulation of tumor
microenvironment and immune cell function. Curr Opin Biotechnol.
84:1030082023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
John SV, Seim GL, Erazo-Flores BJ, Votava
JA, Urquiza US, Arp NL, Steill J, Freeman J, Carnevale LN, Roberts
I, et al: Classically activated macrophages undergo functionally
significant nucleotide metabolism remodelling driven by nitric
oxide. Nat Metab. 7:1681–1702. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Yang L, Li A, Yu W, Wang H, Zhang L, Wang
D, Wang Y, Zhang R, Lei Q, Liu Z, et al: Blockade of purine
metabolism reverses macrophage immunosuppression and enhances
anti-tumor immunity in non-small cell lung cancer. Drug Resist
Updat. 78:1011752025. View Article : Google Scholar
|
|
156
|
Lu Y, Sun Q, Guan Q, Zhang Z, He Q, He J,
Ji Z, Tian W, Xu X, Liu Y, et al: The XOR-IDH3α axis controls
macrophage polarization in hepatocellular carcinoma. J Hepatol.
79:1172–1184. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Shen J, Liao B, Gong L, Li S, Zhao J, Yang
H, Gong Y and Li Y: CD39 and CD73: Biological functions, diseases
and therapy. Mol Biomed. 6:972025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhang Y, Jin W, Deng Z, Gao B, Zhu Y, Fu
J, Xu C, Wang W, Bai T, Jiao L, et al: Metabolic reprogramming
nanomedicine potentiates colon cancer sonodynamic immunotherapy by
inhibiting the CD39/CD73/ADO pathway. Acta Pharm Sin B.
15:2655–2672. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Allard D, Cormery J, Bricha S, Fuselier C,
Abbas Aghababazadeh F, Giraud L, Skora E, Haibe-Kains B and Stagg
J: Adenosine uptake through the nucleoside transporter ENT1
suppresses antitumor immunity and T-cell pyrimidine synthesis.
Cancer Res. 85:692–703. 2025. View Article : Google Scholar
|
|
160
|
Yang H, Lei MML, Xie L, Shou Y and Lee
TKW: Deciphering adenosine signaling in hepatocellular carcinoma:
Pathways, prognostic models, and therapeutic implications. Clin Mol
Hepatol. 31:706–729. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
He X, Cui J, Ma H, Abuduaini N, Huang Y,
Tang L, Wang W, Zhang Y, Wang Y, Lu W, et al: Berberrubine is a
novel and selective IMPDH2 inhibitor that impairs the growth of
colorectal cancer. Biochem Pharmacol. 218:1158682023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Wang L, Yang R, Kong Y, Zhou J, Chen Y, Li
R, Chen C, Tang X, Chen X, Xia J, et al: Integrative single-cell
and bulk transcriptomes analyses reveals heterogeneity of
serine-glycine-one-carbon metabolism with distinct prognoses and
therapeutic vulnerabilities in HNSCC. Int J Oral Sci. 16:442024.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Liu SS, Li JS, Xue M, Wu WJ, Li X and Chen
W: LncRNA UCA1 participates in de novo synthesis of guanine
nucleotides in bladder cancer by recruiting TWIST1 to increase
IMPDH1/2. Int J Biol Sci. 19:2599–2612. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Burrell AL and Kollman JM: IMPDH
dysregulation in disease: A mini review. Biochem Soc Trans.
50:71–82. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Jia HW, Yang HL, Xiong ZL, Deng MH, Wang
T, Liu Y and Cheng M: Design, synthesis and antitumor activity
evaluation of novel indole acrylamide derivatives as IMPDH
inhibitors. Bioorg Chem. 129:1062132022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Naffouje R, Grover P, Yu H, Sendilnathan
A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S and
Sasaki AT: Anti-tumor potential of IMP dehydrogenase inhibitors: A
century-long story. Cancers (Basel). 11:13462019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Zerhouni M, Martin AR, Furstoss N,
Gutierrez VS, Jaune E, Tekaya N, Beranger GE, Abbe P, Regazzetti C,
Amdouni H, et al: Dual covalent inhibition of PKM and IMPDH targets
metabolism in cutaneous metastatic melanoma. Cancer Res.
81:3806–3821. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Sezaki M and Huang G: Repurposing
immunosuppressants for antileukemia therapy. EMBO Mol Med.
15:e170422023. View Article : Google Scholar :
|
|
169
|
Schnabel JL, Frost TC, Wang AC,
Ananthapadmanabhan V, Gurram S, Soroko KM, Gokhale PC and DeCaprio
JA: IMPDH inhibition induces DNA replication stress and ATR
sensitivity in Merkel cell carcinoma. iScience. 28:1125672025.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Tuncyurek P, Mayer JM, Klug F, Dillmann S,
Henne-Bruns D, Keller F and Stracke S: Everolimus and mycophenolate
mofetil sensitize human pancreatic cancer cells to gemcitabine in
vitro: A novel adjunct to standard chemotherapy? Eur Surg Res.
39:380–387. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Floryk D and Huberman E: Mycophenolic
acid-induced replication arrest, differentiation markers and cell
death of androgen-independent prostate cancer cells DU145. Cancer
Lett. 231:20–29. 2006. View Article : Google Scholar
|
|
172
|
Messina E, Micheli V and Giacomello A:
Guanine nucleotide depletion induces differentiation and aberrant
neurite outgrowth in human dopaminergic neuroblastoma lines: A
model for basal ganglia dysfunction in Lesch-Nyhan disease.
Neurosci Lett. 375:97–100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Dun B, Sharma A, Teng Y, Liu H, Purohit S,
Xu H, Zeng L and She JX: Mycophenolic acid inhibits migration and
invasion of gastric cancer cells via multiple molecular pathways.
PLoS One. 8:e817022013. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Takebe N, Cheng X, Wu S, Bauer K,
Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A,
Shaughnessy J, et al: Phase I clinical trial of the inosine
monophosphate dehydrogenase inhibitor mycophenolate mofetil
(cellcept) in advanced multiple myeloma patients. Clin Cancer Res.
10:8301–8308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Rodríguez-Pascual J, Sha P, García-García
E, Rajeshkumar NV, De Vicente E, Quijano Y, Cubillo A, Angulo B,
Hernando O and Hidalgo M: A preclinical and clinical study of
mycophenolate mofetil in pancreatic cancer. Invest New Drugs.
31:14–19. 2013. View Article : Google Scholar
|
|
176
|
Koonrungsesomboon N, Teeyakasem P, Dukaew
N, Sirikaew N, Thongkumkoon P, Yongpitakwattana P, Thepbundit V,
Chaiyawat P, Klangjorhor J, Sakuludomkan C, et al: Efficacy and
safety of mycophenolate mofetil in patients with high-grade locally
advanced or metastatic osteosarcoma (ESMMO): A multicenter, phase
II clinical trial. Int J Clin Oncol. 30:2362–2374. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Torres-Diz M, Reglero C, Falkenstein CD,
Castro A, Hayer KE, Radens CM, Quesnel-Vallières M, Ang Z, Sehgal
P, Li MM, et al: An alternatively spliced gain-of-function NT5C2
isoform contributes to chemoresistance in acute lymphoblastic
leukemia. Cancer Res. 84:3327–3336. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
De Clercq E: C-nucleosides to be
revisited. J Med Chem. 59:2301–2311. 2016. View Article : Google Scholar
|
|
179
|
Malek K, Boosalis MS, Waraska K, Mitchell
BS and Wright DG: Effects of the IMP-dehydrogenase inhibitor,
Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I.
In vivo studies. Leukemia Res. 28:1125–1136. 2004. View Article : Google Scholar
|
|
180
|
Tricot GJ, Jayaram HN, Lapis E, Natsumeda
Y, Nichols CR, Kneebone P, Heerema N, Weber G and Hoffman R:
Biochemically directed therapy of leukemia with tiazofurin, a
selective blocker of inosine 5'-phosphate dehydrogenase activity.
Cancer Res. 49:3696–3701. 1989.PubMed/NCBI
|
|
181
|
Melink TJ, Von Hoff DD, Kuhn JG, Hersh MR,
Sternson LA, Patton TF, Siegler R, Boldt DH and Clark GM: Phase I
evaluation and pharmacokinetics of tiazofurin
(2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer
Res. 45:2859–2865. 1985.PubMed/NCBI
|
|
182
|
Maroun JA and Stewart DJ: Phase I study of
tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC
286193). Invest New Drugs. 8(Suppl 1): S33–S39. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Stewart DJ, Eisenhauer E, Macdonald DR,
Cairncross JG and Langleben A: Phase II study of tiazofurin in
gliomas in adults. A national cancer institute of Canada study. J
Neurooncol. 15:175–179. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Jayaram HN, Yalowitz JA, Arguello F and
Greene JF Jr: Toxicity and efficacy of benzamide riboside in cancer
chemotherapy models. Curr Med Chem. 9:787–792. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Szekeres T, Sedlak J and Novotny L:
Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate
dehydrogenase induces transferrin receptors in cancer cells. Curr
Med Chem. 9:759–764. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Gharehbaghi K, Sreenath A, Hao Z, Paull
KD, Szekeres T, Cooney DA, Krohn K and Jayaram HN: Comparison of
biochemical parameters of benzamide riboside, a new inhibitor of
IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem
Pharmacol. 48:1413–1419. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Jain J, Ma JG, Furey B, Recher C, Demur C,
Poondru S, Zhang J, Li S, Firestone B, Olson K, et al: The IMPDH
inhibitor VX-944 demonstrates in vivo efficacy in an aggressive
leukemia model. Blood. 104:25302004. View Article : Google Scholar
|
|
188
|
Hamilton JM, Harding MW, Genna T and Bol
DK: A phase I dose-ranging study of the pharmacokinetics,
pharmacodynamics, safety, and tolerability of AVN944, an IMPDH
inhibitor, in healthy male volunteers. J Clin Pharmacol. 49:30–38.
2009. View Article : Google Scholar
|
|
189
|
Garcia-Manero G, Pemmaraju N, Alvarado Y,
Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A,
Mukherjee S, et al: Results of a phase 1/2a dose-escalation study
of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid
leukemia or myelodysplastic syndromes. Leuk Lymphoma. 61:1943–1953.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Yang H, Fang Z, Wei Y, Bohannan ZS,
Gañán-Gómez I, Pierola AA, Paradiso LJ, Iwamura H and Garcia-Manero
G: Preclinical activity of FF-10501-01, a novel
inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid
leukemia. Leuk Res. 59:85–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Ichii M, Oritani K, Murase M, Komatsu K,
Yamazaki M, Kyoden R, Kito N, Nozaki Y, Saito M, Iwamura H and
Kanakura Y: Molecular targeting of inosine-5'-monophosphate
dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK
pathway. Leuk Lymphoma. 59:448–459. 2018. View Article : Google Scholar
|
|
192
|
Levine AM, Shimodaira S and Lai MMC:
Treatment of HCV-related mantle-cell lymphoma with ribavirin and
pegylated interferon alfa. New Engl J Med. 349:2078–2079. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Borden KLB and Culjkovic-Kraljacic B:
Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and
beyond? Leuk Lymphoma. 51:1805–1815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Dunn LA, Fury MG, Sherman EJ, Ho AA,
Katabi N, Haque SS and Pfister DG: Phase I study of induction
chemotherapy with afatinib, ribavirin, and weekly carboplatin and
paclitaxel for stage IVA/IVB human papillomavirus-associated
oropharyngeal squamous cell cancer. Head Neck. 40:233–241. 2018.
View Article : Google Scholar
|
|
195
|
Casaos J, Gorelick NL, Huq S, Choi J, Xia
Y, Serra R, Felder R, Lott T, Kast RE, Suk I, et al: The use of
ribavirin as an anticancer therapeutic: Will it go viral? Mol
Cancer Ther. 18:1185–1194. 2019. View Article : Google Scholar : PubMed/NCBI
|
